Literature DB >> 21612470

Bacterial meningitis in the United States, 1998-2007.

Michael C Thigpen1, Cynthia G Whitney, Nancy E Messonnier, Elizabeth R Zell, Ruth Lynfield, James L Hadler, Lee H Harrison, Monica M Farley, Arthur Reingold, Nancy M Bennett, Allen S Craig, William Schaffner, Ann Thomas, Melissa M Lewis, Elaine Scallan, Anne Schuchat.   

Abstract

BACKGROUND: The rate of bacterial meningitis declined by 55% in the United States in the early 1990s, when the Haemophilus influenzae type b (Hib) conjugate vaccine for infants was introduced. More recent prevention measures such as the pneumococcal conjugate vaccine and universal screening of pregnant women for group B streptococcus (GBS) have further changed the epidemiology of bacterial meningitis.
METHODS: We analyzed data on cases of bacterial meningitis reported among residents in eight surveillance areas of the Emerging Infections Programs Network, consisting of approximately 17.4 million persons, during 1998-2007. We defined bacterial meningitis as the presence of H. influenzae, Streptococcus pneumoniae, GBS, Listeria monocytogenes, or Neisseria meningitidis in cerebrospinal fluid or other normally sterile site in association with a clinical diagnosis of meningitis.
RESULTS: We identified 3188 patients with bacterial meningitis; of 3155 patients for whom outcome data were available, 466 (14.8%) died. The incidence of meningitis changed by -31% (95% confidence interval [CI], -33 to -29) during the surveillance period, from 2.00 cases per 100,000 population (95% CI, 1.85 to 2.15) in 1998-1999 to 1.38 cases per 100,000 population (95% CI 1.27 to 1.50) in 2006-2007. The median age of patients increased from 30.3 years in 1998-1999 to 41.9 years in 2006-2007 (P<0.001 by the Wilcoxon rank-sum test). The case fatality rate did not change significantly: it was 15.7% in 1998-1999 and 14.3% in 2006-2007 (P=0.50). Of the 1670 cases reported during 2003-2007, S. pneumoniae was the predominant infective species (58.0%), followed by GBS (18.1%), N. meningitidis (13.9%), H. influenzae (6.7%), and L. monocytogenes (3.4%). An estimated 4100 cases and 500 deaths from bacterial meningitis occurred annually in the United States during 2003-2007.
CONCLUSIONS: The rates of bacterial meningitis have decreased since 1998, but the disease still often results in death. With the success of pneumococcal and Hib conjugate vaccines in reducing the risk of meningitis among young children, the burden of bacterial meningitis is now borne more by older adults. (Funded by the Emerging Infections Programs, Centers for Disease Control and Prevention.).

Entities:  

Mesh:

Year:  2011        PMID: 21612470     DOI: 10.1056/NEJMoa1005384

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  245 in total

Review 1.  The yin yang of bacterial polysaccharides: lessons learned from B. fragilis PSA.

Authors:  Neeraj K Surana; Dennis L Kasper
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

Review 2.  Neuro-intensive care of patients with acute CNS infections.

Authors:  J David Beckham; Kenneth L Tyler
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Use of corticosteroids and other adjunct therapies for acute bacterial meningitis in adults.

Authors:  Kameshwar Prasad; Nirendra Kumar Rai; Amit Kumar
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

4.  Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis.

Authors:  Denis Grandgirard; Melchior Burri; Philipp Agyeman; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

5.  CSF lactate for accurate diagnosis of community-acquired bacterial meningitis.

Authors:  S Giulieri; C Chapuis-Taillard; K Jaton; A Cometta; C Chuard; O Hugli; R Du Pasquier; J Bille; P Meylan; O Manuel; O Marchetti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-19       Impact factor: 3.267

6.  Acute Bacterial Meningitis: Challenges to Better Antibiotic Therapy.

Authors:  Colin Kietzman; Elaine Tuomanen
Journal:  ACS Infect Dis       Date:  2019-07-03       Impact factor: 5.084

Review 7.  Pneumococcal vaccine and patients with pulmonary diseases.

Authors:  Mehdi Mirsaeidi; Golnaz Ebrahimi; Mary Beth Allen; Stefano Aliberti
Journal:  Am J Med       Date:  2014-05-20       Impact factor: 4.965

8.  Enteroviral meningitis does not exclude concurrent bacterial meningitis.

Authors:  Romain Basmaci; Patricia Mariani; Géraldine Delacroix; Sonia Azib; Albert Faye; Muhamed-Kheir Taha; Edouard Bingen; Stéphane Bonacorsi; José R Romero; Harley A Rotbart; Ann-Christine Nyquist; Frederick S Nolte
Journal:  J Clin Microbiol       Date:  2011-09       Impact factor: 5.948

9.  Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.

Authors:  Tyler D Moeller; Kevin B Weyant; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

10.  Edaravone attenuates hippocampal damage in an infant mouse model of pneumococcal meningitis by reducing HMGB1 and iNOS expression via the Nrf2/HO-1 pathway.

Authors:  Zheng Li; Qian-Qian Ma; Yan Yan; Feng-Dan Xu; Xiao-Ying Zhang; Wei-Qin Zhou; Zhi-Chun Feng
Journal:  Acta Pharmacol Sin       Date:  2016-08-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.